Leishmania East Africa Platform Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01360762
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Leishmania East Africa Platform (LEAP)

Active Ingredients

Drugs in Phase 3 Trials (1)

pentamidine (pentam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 3)

Leishmaniasis, Visceral (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1